Arturo Molina Biography and Net Worth

Chief Medical Officer of Protagonist Therapeutics

Dr. Molina joined Protagonist in November 2022 after five years as Chief Medical Officer at Sutro Biopharma. Prior to Sutro, Dr. Molina was Vice President, Oncology Scientific Innovation at Johnson & Johnson. Earlier in his career, Dr. Molina was Chief Medical Officer at Cougar Biotechnology, acquired by Johnson & Johnson in 2009. From 1991 to 2002, Dr. Molina was a faculty staff physician in the Department of Hematology/Bone Marrow Transplantation and Department of Medical Oncology/Therapeutics Research at City of Hope Comprehensive Cancer Center and Adjunct Professor from 2002 to 2004. Dr. Molina earned his M.D. and M.S. in physiology degrees from Stanford University Medical Center, and a B.A. in psychology and B.S. in zoology from the University of Texas at Austin. Dr. Molina maintains an Adjunct Clinical Faculty appointment in the Department of Medicine, Division of Oncology, Stanford University School of Medicine.

What is Arturo Molina's net worth?: The estimated net worth of Arturo Molina is at least $3.88 million as of March 13th, 2025. Dr. Molina owns 83,892 shares of Protagonist Therapeutics stock worth more than $3,882,522 as of April 17th. This net worth evaluation does not reflect any other assets that Dr. Molina may own. Learn More about Arturo Molina's net worth.
How do I contact Arturo Molina?: The corporate mailing address for Dr. Molina and other Protagonist Therapeutics executives is 7707 GATEWAY BOULEVARD SUITE 140, NEWARK CA, 94560. Protagonist Therapeutics can also be reached via phone at (510) 474-0170 and via email at bkorb@soleburytrout.com. Learn More on Arturo Molina's contact information.
Has Arturo Molina been buying or selling shares of Protagonist Therapeutics?: Arturo Molina has not been actively trading shares of Protagonist Therapeutics over the course of the past ninety days. Most recently, Arturo Md Molina sold 30,514 shares of the business's stock in a transaction on Thursday, March 13th. The shares were sold at an average price of $55.74, for a transaction totalling $1,700,850.36. Following the completion of the sale, the insider now directly owns 83,892 shares of the company's stock, valued at $4,676,140.08. Learn More on Arturo Molina's trading history.
Who are Protagonist Therapeutics' active insiders?: Protagonist Therapeutics' insider roster includes Asif Ali (EVP, CFO), Suneel Gupta (Chief Development Officer), David Liu (Insider), Arturo Molina (Chief Medical Officer), Dinsesh Patel (CEO), and William Waddill (Director). Learn More on Protagonist Therapeutics' active insiders.
Are insiders buying or selling shares of Protagonist Therapeutics?: In the last year, insiders at the sold shares 14 times. They sold a total of 349,076 shares worth more than $16,129,383.94. The most recent insider tranaction occured on March, 17th when Director William D Waddill sold 4,000 shares worth more than $217,000.00. Insiders at Protagonist Therapeutics own 5.4% of the company. Learn More about insider trades at Protagonist Therapeutics.
Information on this page was last updated on 3/17/2025.

Arturo Molina Insider Trading History at Protagonist Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
3/13/2025	Sell	30,514	$55.74	$1,700,850.36	83,892
11/27/2024	Sell	26,000	$44.70	$1,162,200.00	46,444
11/15/2024	Sell	1,906	$40.98	$78,107.88	46,444

Arturo Molina Buying and Selling Activity at Protagonist Therapeutics

Protagonist Therapeutics Company Overview

Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis. The company has a license and collaboration agreement with Takeda to commercialize rusfertide; and JNJ Innovative Medicines to co-develop Interleukin-23 receptor antagonist compound JNJ-2113. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.

Today's Range

Now: $46.28

$45.80

$46.87

50 Day Range

MA: $44.68

$35.09

$59.76

2 Week Range

Now: $46.28

$24.22

$60.60

Volume

517,389 shs

Average Volume

842,636 shs

Market Capitalization

$2.84 billion

P/E Ratio

17.40

Dividend Yield

N/A

Beta

2.3